KESHO

Sarcoma Care
2025-07-24 19:00 - 20:30 (Africa/Nairobi)
Bridging Gaps in Soft Tissue Sarcoma Care
Date: 24 July 2025 | 7:00 – 8:30pm EAT
Moderator: Dr Rose Munge
Dr Mohammed Ezzi – Beyond the Visible: Unmasking Soft Tissue Sarcoma in the Heart of Africa
Soft tissue sarcomas are rare malignant tumors of mesenchymal origin, accounting for under 1% of adult cancers. A review at Kenyatta National Hospital showed large tumor sizes (avg. 13 cm), high recurrence (78%), and better outcomes with radical excisions.
Chemotherapy regimens in Ethiopia predominantly included Adriamycin-based combinations. However, access to radiotherapy remains limited, impacting outcomes. Timely radiotherapy, as seen in Tanzania, improves survival.
Key gaps include limited resources, lack of local treatment guidelines, and minimal access to specialists. Future efforts should focus on building regional sarcoma centers, local research, and developing Africa-specific management guidelines.

Endometrial Cancer
2025-07-17 19:00 - 20:30
Moderator: Dr Anisa Mburu
1. Dr. Caroline Tonio – Advanced Endometrial Cancer
Dr. Tonio’s presentation highlighted significant advancements in the treatment of advanced and recurrent endometrial cancer. With rising incidence and poor outcomes in late-stage disease, treatment has evolved from conventional chemotherapy to biomarker-driven strategies.
Molecular subtyping, as identified by the TCGA, has enabled the use of immune checkpoint inhibitors (ICIs) and targeted therapies. Notably, ICIs like dostarlimab and pembrolizumab show strong efficacy in dMMR/MSI-H tumors. Emerging combinations of ICIs with chemotherapy or TKIs are improving survival outcomes. The integration of molecular profiling is now essential in selecting optimal therapies. Future care will increasingly rely on predictive biomarkers to guide personalized treatment.
2. Dr. Khadija Warfa – Endometrial Cancer Pathology and Surgical Staging
Dr. Warfa provided an overview of the pathology, risk factors, and staging of endometrial cancer. Most cases occur in postmenopausal women, with abnormal bleeding as a common symptom. Risk factors include estrogen exposure, obesity, and genetic syndromes.
Diagnosis relies on biopsy and imaging. Pathologically, cancers are divided into Type I and II, with molecular subtypes (e.g., POLE, dMMR, p53-abn) offering greater prognostic value.
Standard surgical management involves hysterectomy with lymph node assessment. Sentinel lymph node biopsy is preferred in many cases due to lower complication rates. Minimally invasive approaches offer comparable survival outcomes with reduced morbidity.

Prostate Cancer
2025-07-10 19:00 - 20:30
Date: 10 July 2025 | Time: 7:00 – 8:30PM EAT
Moderator: Dr Ahmed Komen
Dr Muigai Mararo – Management Algorithm for Metastatic Prostate Cancer
Dr Mararo presented a concise framework detailing oligometastatic local therapies (stereotactic radiotherapy or nodal resection), first‑line androgen‑deprivation therapy (continuous orchiectomy or LHRH analogue) combined with AR pathway inhibitors or docetaxel (with or without triplet combinations), radiotherapy for low‑volume disease, and the sequencing of novel agents (second‑generation antiandrogens, PARP inhibitors, radioligand therapy) in castration‑resistant settings, alongside essential supportive measures (bone protection, multidisciplinary review).
Dr. Syokau Ilovi – Role of Germline Genetic Testing in Prostate Cancer
About 10% of prostate cancers harbor pathogenic germline variants (notably BRCA1/2 and other HRR genes), prompting universal testing in metastatic disease and selective panels in high‑risk localized cases; implementation includes multigene panels, variant classification (pathogenic, VUS), genetic counseling, cascade testing for relatives, and periodic reclassification to inform personalized therapy and family risk management.
Dr. Mercy Gatua – Advances in Management of Metastatic Prostate Cancer: The Role of PARP Inhibitors
PARP inhibitors exploit homologous recombination repair deficiencies (up to 30% of mCRPC, especially BRCA2 mutations) by inducing lethal double‑strand DNA breaks; key trials (TOPARP, PROfound, TRITON3, PROpel) demonstrate significant rPFS and OS benefits as monotherapy or combined with AR pathway inhibitors in germline/somatic HRR‑mutated cohorts, supporting FDA/EMA approvals and integration into first‑line and later‑line mCRPC treatment algorithms.

Lymphoma Management in Africa
2025-07-03 19:00 - 20:30
Date: 3 July 2025 | Time: 7:00 – 8:30 PM EAT
Moderator: Dr Beatrice Jepngetich
Dr. Anne Mwirigi – Relapsed/Refractory DLBCL
Dr. Anne Mwirigi presented a stage IVB germinal-center DLBCL case to illustrate why approximately 14% of Kenyan patients fail standard R-CHOP, highlighting that true primary-refractory disease carries a median survival under nine months. She emphasized early risk stratification using IPI scoring, interim PET imaging, and molecular markers to identify high-risk individuals. For chemosensitive relapses, salvage regimens such as R-GDP and R-ICE can bridge to autologous stem cell transplant; however, CAR-T therapy and CD3×CD20 bispecific antibodies deliver the highest response rates. Practical recommendations included confirming residual disease with biopsy, accelerating cellular therapy referral in primary-progressive cases, and advocating for regional access programs to overcome cost barriers.
Dr. Jonathan Wawire – High-Grade B-Cell Lymphoma Entities
Dr. Jonathan Wawire decoded the WHO 5th-edition classification of high-grade B-cell lymphomas, clarifying that a Ki-67 index ≥80% and dual MYC/BCL2 or BCL6 rearrangements define the most aggressive subtypes. He noted Kenya’s elevated prevalence of non-GCB and double-expresser lymphomas, which correlate with poorer outcomes and necessitate intensified regimens. Key diagnostic insights included routine Ki-67 quantification, Hans/Choi cell-of-origin algorithms, and reflex FISH panels for precise double-hit detection. He stressed that accurate subclassification is essential for deciding when to intensify therapy beyond R-CHOP—such as DA-EPOCH-R—or to enrol patients in clinical trials, ensuring truly personalized care for aggressive lymphoma in African settings.

Sickle Cell Disease
2025-06-25 19:00 - 20:30

Sickle Cell Disease
2025-06-19 19:00 - 20:30
Date: 19 June 2025 | Time: 7:00 – 8:30 PM EAT
Moderator: Dr Peter Oyiro
Prof. Jessie Githang’a – Sickle Cell Clinical Trials in Kenya
Prof. Jessie Githang’a emphasized the need for more SCD clinical trials in Africa, where the disease burden is greatest. She outlined the underrepresentation of African populations in global trials and highlighted the benefits of local research, including better understanding of drug efficacy, safety, and socio-genetic differences. She discussed ongoing and past trials in Kenya involving Hydroxyurea, Crizanlizumab, and gene therapies, noting challenges like infrastructure gaps and limited expertise. Prof. Githang’a called for improved research capacity, team collaboration, and greater engagement with trial participants.
Dr. Doreen Mutua – Management of SCD in the 21st Century
Dr. Doreen Mutua reviewed modern SCD management, highlighting the importance of early diagnosis, health maintenance, and Hydroxyurea therapy. She addressed common complications like stroke, chronic pain, and organ damage, and emphasized early intervention to prevent progression. Transition of care for adolescents, genetic counseling, and curative options such as HSCT and gene editing were also discussed. Her presentation underscored the need for advocacy, access to comprehensive care, and integration of newborn screening into national systems.

Cancer and Nutrition
2025-06-18 19:00 - 20:30

Clinical Nutrition in Cancer
2025-06-12 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Moderator: Dr Catherine Nyongesa
Speakers & Topics:

Kennedy Okinda: Medical Nutrition Therapy Cases in Cancer Care – A Cross‑Sector Lens
Traceyann Njeri Wacheke: Medical Nutrition Therapy in Survivorship & Secondary Cancer Prevention

Palliative Care: Integrative Oncology
2025-06-11 19:00 - 20:30

Cancer Survivor's Day
2025-06-05 19:00 - 20:30
Moderator: Prof John Weru
Speakers & Topics:

Muthoni Mate: Tokenism in Cancer Survivor Involvement – Beyond Being the Face on a Brochure
Dr Mary Nyangasi: Beyond Remission – Best Practices in Survivorship Care Planning & Patient Navigation
Dr Esther Muinga: Palliative Care as a Pillar of Survivorship

Muthoni Mate highlighted the issue of tokenism where survivors are symbolically included without influence. She called for shifting from consultation to co-design and recognizing survivors as experts by experience. Obstacles include medical jargon, lack of trauma-informed engagement, minimal institutional support, and preference for academic voices. True engagement must be collaborative, compensated, and empowering, allowing survivors to shape policy and practice. She urged stakeholders to move beyond the ‘face on the brochure’ and include survivors meaningfully in healthcare decision-making.
Dr. Nyangasi emphasized the critical role of survivorship care planning and patient navigation in ensuring long-term quality of life for cancer survivors. She outlined survivorship as a continuum beginning at diagnosis, extending beyond acute care into surveillance, psychosocial support, and lifestyle guidance. Evidence from over 60 systematic reviews shows that patient navigation improves care access, adherence to follow-up, and satisfaction. Barriers in Kenya include weak health systems, low awareness, lack of funding, and absence of integrated care protocols. There is urgent need for structured survivorship models and investment in navigation programs with proven return on investment.
Dr. Muinga presented palliative care as integral to survivorship, aiming to improve quality of life through pain control, emotional support, and end-of-life care. She emphasized the interconnectedness of palliation, prevention, and health promotion. Effective survivorship care requires collaboration across disciplines and includes surveillance, psychosocial screening, and health education. Survivorship plans should empower patients and caregivers, incorporate national policies, and address financial and cultural challenges. She concluded that palliative care is not about dying—it’s about living fully post-treatment.

Cancer Survivorship
2025-06-04 19:00 - 20:30

Brain Cancer / Brain Tumour
2025-05-28 19:00 - 20:30

EA Oncology Summit
2025-05-24 08:30 - 16:00 | Virtual Event (Zoom), Kenya
Loading Viewer...

Multidisciplinary Approaches to Paediatric Brain Tumours
2025-05-22 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Moderator: Dr Alfred Odhiambo
Speakers & Topics:

Mr David L. Oluoch‑Olunya: Surgical Management of Paediatric Brain Tumours
Dr Michael Magoha: Endocrinological Management of Paediatric Brain Tumours
Dr Ahmed Korir: Radiation Therapy in Paediatric Brain Tumours

Mr. David Oluoch-Olunya presentation summary
– Over 25 years, Kenya has moved from fragmented care to growing multidisciplinary tumour boards in urban centres.
– Key challenges remain: late diagnosis, radiotherapy access disparities, and poor survivorship follow-up.
– Regional initiatives like the Brain Tumor Consortium of Africa (BTCoA) aim to standardize care and improve data sharing.
– Priorities: expand MDT care to counties, national paediatric tumour registry, survivorship and rehab programs.
– Kenya has made major strides, but gaps persist in early detection, diagnostics, and referral systems.
Dr Ahmed Komen’s presentation summary
– RT use depends on age, tumour type/location, other treatments, and disease extent.
– Modern RT techniques include 2D, 3DCRT, IMRT, VMAT, and proton therapy (where available).
– RT aims: radical (curative) or palliative (symptom relief).
– RT delivery to children requires precise planning and often sedation or anaesthesia.
– Late effects of RT: cognitive decline, growth delay, hearing loss, hormonal dysfunction, secondary cancers.
– Younger age (<7 yrs) and higher doses correlate with greater neurocognitive risks.
– Proton therapy offers tissue-sparing benefits but has limited availability in LMICs.

Bladder Cancer
2025-05-15 19:00 - 20:30
Moderator: Roselyne A. Okumu
Speakers & Topics:

Dr Melissa Reimers: Updates in the Management of Advanced Bladder Cancer
Prof Peter Mungai: Superficial Bladder Cancer Management

Management of Non-Muscle-Invasive Bladder Cancer (NMIBC)
– NMIBC represents ~75% of new bladder cancer cases, typically presenting with painless hematuria.
– Diagnosis: Cystoscopy and TURBT; blue light cystoscopy improves detection.
– Risk-based treatment approach:
• Low/intermediate-risk: single post-op intravesical chemo (mitomycin C/gemcitabine)
• High-risk: 6-week BCG induction ± maintenance
– BCG-unresponsive NMIBC: radical cystectomy or emerging therapies.
– Promising bladder-sparing agents: TAR-200 (gemcitabine) and TAR-210 (erdafitinib).
– Trials (MoonRISe-3, SunRISe-5) show >80% DFS in high-risk patients.
Updates in Advanced and Metastatic Bladder Cancer
– Bladder cancer is the 4th most common male cancer globally.
– Molecular profiling is critical: test for FGFR3 and HER2.
– 1st-line standard: Enfortumab vedotin + Pembrolizumab (EV-302/KEYNOTE-A39).
– Platinum-eligible: Cis/gem ± nivolumab; Carb/gem → Avelumab maintenance.
– 2nd/3rd-line: Erdafitinib (FGFR+), T-DXd (HER2+).
– Novel ADCs (Enfortumab, Sacituzumab) offer superior outcomes to chemo.
– Trial enrolment is encouraged for all patients.
Key Clinical Takeaways
– Intravesical innovation is changing NMIBC treatment beyond BCG.
– Biomarker-driven therapy is now essential for managing advanced bladder cancer.
– Routine molecular testing is critical for individualized care

Melanoma/Skin Cancer
2025-05-14 19:00 - 20:30

Management of Indolent Lymphomas
2025-05-08 19:00 - 20:30
Moderator: Prof Nicholas Otieno Abinya
Speakers & Topics:

Dr Samson Mutanda: Practical Approaches in Clinical Case‑Driven Exploration
Prof Shahin Sayed: Histopathology & Low‑Grade Lymphomas
Dr Matilda Ongondi: CT Treatment Algorithm – A Practical Approach

Dr. Samson Mutanda – presented case-based exploration of CLL management in Kenyan settings.
– Key clinical points:
• CLL is heterogeneous and often indolent; many patients start with watchful waiting.
• Symptomatic cytopenias and disease progression warrant treatment.
• Therapy included bendamustine, rituximab, venetoclax, and novel agents like ibrutinib.
– Highlighted diagnostic limitations due to access to FISH, molecular testing, and cost of targeted therapies.
– Underscored importance of tailored care, especially in young patients and those with co-morbidities.
Dr. Matilda Ongondi – Provided a clinical introduction to indolent lymphomas, which are slow-growing B-cell neoplasms such as CLL/SLL, follicular lymphoma, and MZL.
– Emphasized the necessity for clinical vigilance and long-term monitoring.
– Stressed the need for diagnostic precision, the role of immunophenotyping, and the heterogeneity of clinical presentations.
– Highlighted treatment considerations: watchful waiting, targeted therapy, and challenges in resource-limited settings.
Prof. Shahin Sayed – Reviewed WHO-HEM5 classification of indolent lymphomas, emphasizing pathology-driven subtypes.
– Covered key immunophenotypic markers: CD5, CD23, LEF1, BCL2, Cyclin D1, etc.
– Presented rare pediatric and adolescent cases, illustrating diagnostic complexity and variability.
– Detailed histologic signs of aggressive transformation (e.g. high Ki-67, prolymphocytic features).
– Outlined molecular diagnostics: del(11q, 13q, 17p), TP53 mutations, IGHV SHM – all important for prognosis and treatment.
– Discussed evolving terminology: classic FL, follicular lymphoma with uncommon features (uFL), and follicular large cell lymphoma.

Open
2025-05-07 19:00 - 20:30

Testicular Cancer
2025-04-30 19:00 - 20:30

Advanced Ovarian Cancer
2025-04-24 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Moderator: Prof Rose J. Kosgei
Speakers & Topics:

Prof Omenge Orang’o: Management of Epithelial Ovarian Cancer
Dr Peter Oyiro: PARP Inhibitors in Ovarian Cancer
Dr Charles Muteshi: Fertility Preservation in Ovarian Cancer

Epidemiology and Diagnosis (Prof. Omenge Oran’go)
– Ovarian cancer remains a significant cause of cancer mortality among women due to its asymptomatic nature in early stages.
– Kenya sees many cases diagnosed at advanced stages (III/IV), primarily due to non-specific symptoms and lack of screening.
– Important to understand pelvic anatomy and tumor spread patterns for accurate diagnosis and surgical planning.
Fertility Preservation in Ovarian Cancer (Dr. Charles Muteshi)
– Fertility-sparing surgery should be considered in selected early-stage epithelial ovarian cancers (Stage I).
– Discussion on embryo/oocyte cryopreservation for patients undergoing gonadotoxic treatment.
– Emphasized need for multidisciplinary counseling and prompt fertility consultations to ensure oncologic safety and reproductive potential.
Role of PARP Inhibitors (Dr. Peter Oyiro)
– PARP inhibitors like Olaparib offer significant benefits in BRCA-mutated and homologous recombination-deficient (HRD) ovarian cancers.
– SOLO-1 and SOLO-2 studies demonstrated prolonged progression-free survival and delayed recurrence in both frontline and maintenance settings.
– 7-year follow-up data show sustained benefit, with over 48% progression-free survival in Olaparib arms.
– Low incidence of serious adverse events, with anemia, fatigue, and nausea as the most common.
– Highlighted integration into Kenya Cancer Treatment Guidelines and importance of HRD testing.

World AML Day (21st)
2025-04-23 19:00 - 20:30

Bladder Cancer
2025-04-21 19:00 - 20:30

Head & Neck Cancer
2025-04-16 19:00 - 20:30

Esophageal Cancer CME
2025-04-10 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Esophageal Cancer CME – Experience from a Regional Cancer Centre
Moderator: Dr Tracy Irura
Speakers & Topics:

Dr Omar Abdihamid: Evolving Landscape of Esophageal Cancer Treatment
Dr Abdullahi Hadi: Optimising Diagnosis of Esophageal Cancer
Dr Mohamed Noor: Surgical Approaches to Esophageal Cancer

Dr. Noor Mohamed provided a historical evolution of esophageal cancer surgery from Czerny’s resection to modern minimally invasive techniques.
– Surgical resection remains critical, especially for early-stage and select advanced cases after neoadjuvant therapy.
– Key considerations include thorough staging (OGD, PET-CT, EUS), patient optimization (nutrition, glycemic control), and perioperative care.
– Outcomes from global surgical databases: R0 resection rates up to 93%, 30- and 90-day mortality rates at 2% and 4.5% respectively.
– Challenges in Kenya include late presentation, limited access to ICU care, and lack of trained personnel.
– Trials such as CROSS, PreSANO, and SANO are shaping modern surveillance versus resection decisions in select cases.
Dr. Omar Abdihamid – emphasized that most patients in Kenya present with locally advanced disease; male/female incidence is similar.
– Immunotherapy has shifted paradigms: CheckMate 648 showed improved OS with nivolumab + chemotherapy or ipilimumab.
– CROSS and ESOPEC trials guide perioperative regimens (carbo/taxol RT → surgery → nivolumab vs FLOT-based therapy).
– Early-stage SCC may be treated with endoscopic resection if well-differentiated, superficial, and no lymphovascular invasion.
– Radiotherapy regimens tailored by location: cervical tumors dose-escalated up to 60Gy; others typically 50.4Gy.
– Garissa Cancer Centre approach includes advanced IMRT planning, with regional data contributing to genomic and QoL research.
– SANO trial supports non-inferiority of active surveillance post-chemoradiotherapy, showing similar OS to surgery and better QoL.

Esophageal Cancer
2025-04-09 19:00 - 20:30

Head and Neck Cancer
2025-04-03 19:00 - 20:30 | Virtual Event (Zoom), Kenya
Moderator: Dr Angela Waweru
Speakers & Topics:

Dr Harish Nagaraj: Radiologic Imaging of Head & Neck Cancers
Dr Solomon Mutua: Role of PET/CT Scan in Head & Neck Imaging

Dr. Solomon Mutua emphasized the value of PET/CT in radiotherapy planning:
– PET/CT allows for biologic imaging of tumors, identifying hypoxic and metabolically active subvolumes.
– Integration improves accuracy in delineating gross tumor volume (GTV), allowing for dose escalation while minimizing toxicity.
– Particularly beneficial in cases with occult primaries, equivocal CT/MRI, and in adaptive RT strategies.
– PET/CT-based contouring can reduce geographical misses and optimize nodal staging and treatment response.
– Hypoxia imaging and dose painting are under investigation to further personalize radiotherapy protocols.

Bowel Cancer
2025-04-02 19:00 - 20:30

Management of Kidney Cancer
2025-03-27 19:00 - 20:30
Moderator: Dr Jonathan Wala
Speakers & Topics:

Dr Amina K. Habib: Optimizing Kidney Cancer Care
Dr Patrick Mbuthia: Surgical Aspects of Kidney Cancer Management

Diagnosis and Evaluation
– RCC includes clear cell, papillary, chromophobe, and rare subtypes.
– Classic triad (flank pain, hematuria, mass) is rare and suggests late-stage disease.
– Paraneoplastic syndromes present in ~30% of cases.
– Imaging: Ultrasound (cystic lesions), MRI/CT (staging), and renal function tests.
– Renal biopsy recommended for indeterminate lesions, small masses for surveillance, or metastatic confirmation.
Surgical Management
– Partial nephrectomy preferred in localized RCC for nephron-sparing and better long-term outcomes.
– Thrombectomy improves survival in non-metastatic RCC with IVC involvement.
– Cytoreductive nephrectomy and metastasectomy have roles in selected metastatic cases.
Upper Tract Urothelial Carcinoma (UTUC)
– Represents 5–10% of urothelial cancers, commonly presents with hematuria.
– Risk factors: smoking, aristolochic acid, arsenic exposure, Lynch syndrome.
– Diagnostic tools: CT/MRI, cystoscopy, urinary cytology, retrograde pyelography, ureteronephroscopy.
Management of UTUC
– Low-risk: Endoscopic ablation + topical chemotherapy.
– High-risk localized: Radical nephroureterectomy + bladder cuff removal, postoperative intravesical chemotherapy.
– Role of lymph node dissection and neoadjuvant chemotherapy is still being defined.

International Women’s Day Women in Oncology
2025-03-26 19:00 - 20:30

Colorectal Cancer
2025-03-26 19:00 - 20:30
